HDAC9 and neoplasm: For example, activation of the YAP/TAZ signaling pathway can promote tumor cell growth (53), whereas histone deacetylase (HDAC) inhibitors increase histone acetylation by inhibiting HDAC activity, thereby affecting epigenetic reprogramming of CAFs (YAP/TAZ signaling pathway) and interfering with their role in promoting drug resistance (54).